2[3]Flockhart DA, Tanus Santos JE.Implications of cytochrome P45o interactions when prescribing medication for hypertension[J].Ach Intern Med, 2000,162:405.
3[4]Sica DA.Rationale for fixed-dose combinations in the treatment of hypertension[J]. Drugs, 2002, 62:443.
4[5]Venkatakrishnan K.Von Moltke LL,Greenblatt DJ.Humen drug metabolism and the cytochromes P450:Application and relevance of in vitro models [J].J Clin Pharmacol,2001,41:1 149.
6Yuan R, Parmelee T, Balian JD, et al. In vitro metabolic interaction studies: Experience of the food and drug administration. Clin Pharmacol Ther, 1999, 66:9.
7Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta- analysis of prospective studies. JAMA,1998,279:1200.
8Friedman MA, Woodcock J, Lumpkin MM, et al. The safety of newly approved medicines - Dorecent market removals mean there is a problem?JAMA, 1999, 281 : 1728.
2Amankwa K, Krishnan S C, Tisdale J E. Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors[J]. Clin Pharmacol Ther,2004,75(3) :242-247.
